|
1
|
Levenson M, He W, Chen J, Fang Y, Faries D, Goldstein BA, Ho M, Lee K, Mishra-Kalyani P, Rockhold F, Wang H, Zink RC. Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Stat Biopharm Res 2021. [DOI: 10.1080/19466315.2021.1883473] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
| | - Weili He
- Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie, North Chicago, IL
| | - Jie Chen
- Overland Pharmaceuticals, Dover, DE
| | - Yixin Fang
- Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie, North Chicago, IL
| | - Douglas Faries
- Global Statistical Sciences, Eli Lilly & Company, Indianapolis, IN
| | - Benjamin A. Goldstein
- Department of Biostatistics & Bioinformatics, Duke University, Durham, NC
- Duke Clinical Research Institute, Duke University, Durham, NC
| | | | - Kwan Lee
- Statistics and Decision Sciences, Janssen Research and Development (retired), Spring House, PA
| | | | - Frank Rockhold
- Department of Biostatistics & Bioinformatics, Duke University, Durham, NC
- Duke Clinical Research Institute, Duke University, Durham, NC
| | - Hongwei Wang
- Global Medical Affairs Statistics, Data and Statistical Sciences, AbbVie, North Chicago, IL
| | | |
Collapse
|
|
2
|
Ball G, Kurek R, Hendrickson BA, Buchanan J, Wang WW, Duke SP, Bhattacharyya A, Li M, O’Brien D, Weigel J, Wang W, Jiang Q, Ahmad F, Seltzer JH, Herrero-Martinez E, Tremmel L. Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Ther Innov Regul Sci 2019. [DOI: 10.1177/2168479019841314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Greg Ball
- Clinical Safety Statistics, Merck Research Laboratories, Rahway, NJ, USA
| | - Raffael Kurek
- Global Patient Safety, Eli Lilly and Company, Windlesham, UK
| | | | | | - William W. Wang
- Clinical Safety Statistics, Merck Research Laboratories, North Wales, PA, USA
| | - Susan P. Duke
- Office of Biostatistics, Center for Drug Evaluation, Food and Drug Administration, Silver Spring, MD, USA
| | | | - Mengchun Li
- Global Alliance for TB Drug Development, New York City, NY, USA
| | - Dennis O’Brien
- Risk Management, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA
| | - Judith Weigel
- Pharmacovigilance, vfa Research-Based Pharmaceutical Companies, Berlin, Germany
| | - Wenquan Wang
- Biostatistics, Sanofi Pasteur, Swiftwater, PA, USA
| | - Qi Jiang
- Biometrics, Seattle Genetics, Bothell, WA, USA
| | - Faiz Ahmad
- US Biostatistics, Galderma R&D, Fort Worth, TX, USA
| | | | | | - Lothar Tremmel
- Biostatistics and Medical Writing, CSL Behring, King of Prussia, PA, USA
| |
Collapse
|
|
3
|
Seltzer JH, Li J, Wang W. Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers. Ther Innov Regul Sci 2019:2168479018793130. [PMID: 30925080 DOI: 10.1177/2168479018793130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section.
Collapse
Affiliation(s)
| | - Judy Li
- 2 Biostatistics, Celgene Corporation, San Diego, CA, USA
| | - William Wang
- 3 Clinical Safety Statistics, Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories, North Wales, PA, USA
| |
Collapse
|